Clinical Trial

OH2 Injection in Combination With HX008 for Melanoma.

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2025 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This phase Ib study evaluates the safety and efficacy of OH2 in combination with HX008, an anti-PD-1 antibody, in patients with Melanoma. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-10-29; most recent amendment 2025-07-22.
Trial Details
NCT Number NCT04616443
Lead Sponsor Binhui Biopharmaceutical Co., Ltd.
Conditions Melanoma
Enrollment 60 participants
Start Date 2020-12-01
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-24